Thank you

This live web event has ended. Thank you for attending.

Description

ACTIVITY OVERVIEW
The addition of the CDK4/6 inhibitor abemaciclib to adjuvant endocrine therapy (ET) improves invasive disease-free and distant recurrence-free survival in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) compared with ET alone. Achieving maximal benefit from these therapies requires years of treatment and, although their oral mode of administration offers convenience, many patients experience significant issues with adherence and persistence throughout the duration of their treatment. This initiative will provide pharmacy professionals with the latest developments and clinical evidence related to the use of CDK4/6 inhibitors in high-risk HR+/HER2- EBC, as well as case-based guidance on strategies to anticipate, address, and counsel patients on potential adverse events (AEs), drug-drug interactions (DDIs), and tolerability considerations that may negatively impact adherence to and persistence with oral therapy.